Drug Trial Radar · NCT02132767
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Mar 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
523
Actual
Start
May 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Icahn School of Medicine at Mount SinaiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); Canadian Institutes of Health Research (CIHR)
- First posted
- May 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the therapeutic strategies of rate control versus rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial fibrillation or atrial flutter (AF). In patients who develop AF during hospitalization after cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days in hospital within 60 days of the occurrence of AF compared to a strategy of rate control.
Conditions
- Postoperative Atrial Fibrillation
Interventions
AmiodaroneDrug
Amiodarone Initial Dose * Oral: 400 mg po TID for 3 days is recommended * For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose * Oral: at least 200 mg/day to be continued until 60 days after randomization * If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
DC-cardioversionProcedure
DC-Cardioversion - frequency and duration determined by medical professional as medically needed
Rate ControlDrug
Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Days in HospitalTime frame: Within 60 days of randomization
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Emory University
Atlanta, Georgia
University of Maryland
Baltimore, Maryland
NIH Heart Center at Suburban Hospital
Bethesda, Maryland
University of Michigan Health Services
Ann Arbor, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
Montefiore Einstein Heart Center
The Bronx, New York
Mission Hospital
Asheville, North Carolina
Duke University
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Baylor College of Medicine
Houston, Texas
Baylor Research Institute
Plano, Texas
University of Virginia Health Systems
Charlottesville, Virginia
University of Wisconsin
Madison, Wisconsin
University of Alberta Hospital
Edmonton, Alberta, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Hôpital du Sacré-Cœur de Montréal
Montreal, Quebec, Canada
Institut Universitaire de Cardiologie de Quebec (Hopital Laval)
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.